The deterioration time of patients with lupus erythematosus varies, depending on the extent of the disease, the physical quality of the patient, the organs involved and whether the patient is actively treated, etc. Specific analysis is needed. Most patients with lupus erythematosus have prolonged and slow progression of the disease. If they actively cooperate with the treatment, have better control, and are able to follow up and review regularly, most of them can be completely controlled and their life expectancy will not be affected. However, if patients stop the medication prematurely without authorization, the disease may deteriorate repeatedly for several years to decades, and serious damage to multiple organs may occur, such as lupus pulmonary lesions, central neurological lupus and acute lupus nephritis, which may endanger patients’ lives. Therefore, once lupus nephritis, hematologic involvement and psychiatric symptoms appear in patients with lupus erythematosus, they should be consulted early and may need high-dose glucocorticoid shock therapy or combined with immunosuppressive drugs, as well as prevention and timely management of hormone adverse reactions during hormone therapy.